Short Interest in Cibus, Inc. (NASDAQ:CBUS) Increases By 46.1%

Cibus, Inc. (NASDAQ:CBUS) was the recipient of a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 1,684,009 shares, a growth of 46.1% from the January 15th total of 1,152,308 shares. Based on an average daily trading volume, of 420,457 shares, the days-to-cover ratio is presently 4.0 days. Currently, 6.1% of the company’s shares are short sold. Currently, 6.1% of the company’s shares are short sold. Based on an average daily trading volume, of 420,457 shares, the days-to-cover ratio is presently 4.0 days.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CBUS. Certior Financial Group LLC increased its position in Cibus by 6.5% in the 3rd quarter. Certior Financial Group LLC now owns 184,786 shares of the company’s stock valued at $238,000 after buying an additional 11,230 shares in the last quarter. Transce3nd LLC boosted its holdings in shares of Cibus by 29.1% in the 2nd quarter. Transce3nd LLC now owns 52,656 shares of the company’s stock worth $75,000 after buying an additional 11,861 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Cibus by 4.7% during the 4th quarter. Geode Capital Management LLC now owns 275,180 shares of the company’s stock worth $479,000 after purchasing an additional 12,467 shares during the last quarter. Raymond James Financial Inc. grew its stake in shares of Cibus by 31.0% during the 2nd quarter. Raymond James Financial Inc. now owns 53,713 shares of the company’s stock worth $74,000 after acquiring an additional 12,722 shares during the period. Finally, Bank of America Corp DE lifted its position in shares of Cibus by 113.4% during the fourth quarter. Bank of America Corp DE now owns 35,536 shares of the company’s stock worth $99,000 after acquiring an additional 18,885 shares in the last quarter. 33.81% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on CBUS shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cibus in a research note on Wednesday, January 21st. Canaccord Genuity Group restated a “buy” rating and issued a $15.00 target price on shares of Cibus in a research report on Monday, December 8th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $20.00.

Cibus Stock Up 15.6%

NASDAQ:CBUS opened at $2.30 on Friday. The firm has a market capitalization of $124.85 million, a PE ratio of -0.71 and a beta of 1.80. The firm has a 50-day moving average price of $1.86 and a 200 day moving average price of $1.56. Cibus has a 12-month low of $1.09 and a 12-month high of $3.40.

Cibus (NASDAQ:CBUS) last announced its earnings results on Thursday, November 13th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.03). The company had revenue of $0.62 million during the quarter, compared to the consensus estimate of $1.39 million. Cibus had a negative return on equity of 133.90% and a negative net margin of 3,133.92%. On average, research analysts expect that Cibus will post -2.96 EPS for the current year.

About Cibus

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.